Huntleigh Advisors Inc. Takes Position in Kamada Ltd. (NASDAQ:KMDA)

Huntleigh Advisors Inc. bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 130,625 shares of the biotechnology company's stock, valued at approximately $863,000. Huntleigh Advisors Inc. owned 0.23% of Kamada as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in KMDA. JPMorgan Chase & Co. purchased a new stake in Kamada during the 4th quarter worth approximately $67,000. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC increased its position in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after purchasing an additional 6,850 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on KMDA shares. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Kamada in a research report on Thursday, May 15th. Sidoti raised shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st.

Kamada Trading Down 2.2%

Shares of NASDAQ KMDA traded down $0.17 during mid-day trading on Monday, reaching $7.71. The company had a trading volume of 63,953 shares, compared to its average volume of 96,223. The firm has a 50 day simple moving average of $7.05 and a two-hundred day simple moving average of $6.91. The stock has a market cap of $443.40 million, a P/E ratio of 26.59, a PEG ratio of 0.96 and a beta of 0.96. Kamada Ltd. has a 52-week low of $5.08 and a 52-week high of $9.16.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. The firm had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. On average, equities analysts expect that Kamada Ltd. will post 0.23 EPS for the current year.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.